Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
03/1999
03/25/1999WO1999014353A2 Intrabody-mediated control of immune reactions
03/25/1999WO1999014345A2 Medicament for treating a manifested lyme disease
03/25/1999WO1999014343A1 Dna encoding a ras carboxyl-terminal processing protein
03/25/1999WO1999014340A1 Human prl-1 phosphatase
03/25/1999WO1999014339A1 ASPARAGINASE PROTEINS, NUCLEIC ACID MOLECULES, AND USES THEREOF OBTAINABLE FROM A PARASITIC HELMINTH, IN PARTICULAR FROM $i(DIROFILARIA IMMITIS)
03/25/1999WO1999014334A1 Peptides derived from the attachment (g) protein of respiratory syncytial virus
03/25/1999WO1999014333A2 Improved method of production of pneumococcal surface proteins
03/25/1999WO1999014330A1 DcR3 POLYPEPTIDE, A TNFR HOMOLOG
03/25/1999WO1999014328A2 Secreted and transmembrane polypeptides and nucleic acids encoding the same
03/25/1999WO1999014326A1 Mage-3 peptides presented by hla class ii molecules
03/25/1999WO1999014317A1 Methods for the diagnosis of feline infectious anemia
03/25/1999WO1999014244A1 Method of affinity cross-linking biologically active, immunogenic peptides to antibodies
03/25/1999WO1999014233A1 Peptides derived from cowdria ruminantium, antibodies thereto and their diagnostical and medical uses
03/25/1999WO1999014230A1 Mammaglobin, a secreted mammary-specific breast cancer protein
03/25/1999WO1999013915A1 Method of delivering genes to antigen presenting cells of the skin
03/25/1999WO1999013912A1 Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis
03/25/1999WO1999013910A1 Neovascularization inhibitor
03/25/1999WO1999013909A1 Corneal neovascularization inhibitors
03/25/1999WO1999013908A1 Compound inhibiting presenilin 1 for preparing a medicine and a diagnostic agent
03/25/1999WO1999013907A2 Methods to improve immunogenicity of antigens and specificity of antibodies
03/25/1999WO1999013906A1 Multivalent vaccines
03/25/1999WO1999013904A1 T-cell vaccination for the treatment of multiple sclerosis
03/25/1999WO1999013903A1 Methods and compositions for diagnosing and treating malaria
03/25/1999WO1999013896A1 Attenuated vif dna immunization cassettes for genetic vaccines
03/25/1999WO1999013818A2 Membrane virus host range mutations and their uses as vaccine substrates
03/25/1999WO1999013720A1 Outer membrane protein of ehrlichia canis and ehrlichia chaffeensis
03/25/1999WO1999009194B1 Recombinant celo avian adenovirus and use as vaccinating vector
03/25/1999WO1999002554A3 Human herpesvirus-7 diagnostic and immunologic reagents and use thereof
03/25/1999WO1999001463A3 Modified glycosides, compositions comprised thereof and methods of use thereof
03/25/1999WO1998057994A3 Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
03/25/1999WO1998054225A3 Human-cd28 specific monoclonal antibodies for antigen non-specific activation of t-lymphocytes
03/25/1999WO1998050067A9 Use or a secretion vector for fertility control by oral vaccination
03/25/1999DE19741607A1 New polypeptides comprising prion protein sequences
03/25/1999CA2382376A1 Novel polypeptides and nucleic acids encoding pro287 which are useful for treating disorders of the pancreas
03/25/1999CA2304373A1 T-cell vaccination for the treatment of multiple sclerosis
03/25/1999CA2304309A1 Dna encoding a ras carboxyl-terminal processing protein
03/25/1999CA2304256A1 Outer membrane protein of ehrlichia canis and ehrlichia chaffeensis
03/25/1999CA2304208A1 Intrabody-mediated control of immune reactions
03/25/1999CA2304167A1 Mammaglobin, a secreted mammary-specific breast cancer protein
03/25/1999CA2304128A1 Improved method of production of pneumococcal surface proteins
03/25/1999CA2304125A1 Attenuated vif dna immunization cassettes for genetic vaccines
03/25/1999CA2304011A1 Compound inhibiting presenilin 1 for preparing a medicine and a diagnostic agent
03/25/1999CA2303834A1 Secreted and transmembrane polypeptides and nucleic acids encoding the same
03/25/1999CA2303775A1 Methods to improve immunogenicity of antigens and specificity of antibodies
03/25/1999CA2303227A1 Human prl-1 phosphatase
03/25/1999CA2303225A1 Dna30942 polypeptide, a tnfr homolog
03/25/1999CA2303178A1 Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis
03/25/1999CA2303105A1 Multivalent vaccines
03/25/1999CA2302316A1 Method of delivering genes to antigen presenting cells of the skin
03/25/1999CA2244978A1 Novel alcohol dehydrogenase
03/25/1999CA2244971A1 Mure
03/25/1999CA2244967A1 Murf
03/25/1999CA2244954A1 Murf
03/24/1999EP0903409A2 Aminopeptidase (AmpS)
03/24/1999EP0903408A2 Tat-derived transport polypeptide
03/24/1999EP0903407A2 Streptococcus pneumoniae phoH gene
03/24/1999EP0903150A1 Regulation of immunoglobulin production by interleukin-9
03/24/1999EP0902837A1 Tailless nuclear hormone receptor (tlx receptor)
03/24/1999EP0902791A1 Extracellular/epidermal growth factor hcaba58x
03/24/1999EP0705346B1 Monoclonal antibodies against the alpha pdgf receptor and uses thereof
03/24/1999EP0534978B1 Interleukin-1 antagonist and uses thereof
03/24/1999CN1211926A Pharmaceutical composition for immunomodulation based on peptides and adjuvants
03/24/1999CN1211924A Immunomodulatory complex for helicobacter bacteria
03/24/1999CN1211578A PEG-inerferon conjugates
03/24/1999CN1211449A Neospora veccine
03/23/1999US5886163 A recombinant nucleic acid molecule which encodes a mutant hiv-1 gp120 envelope glycoprotein comprising a v3 loop deletion and a c4 domains.sub.(w.fwdarw.x) point mutation, wherein x is an amino acid residue other than tryptophan
03/23/1999US5886154 Chromatographic method for high yield purification and viral inactivation of antibodies
03/23/1999US5886152 Humanized antibody produced by transplantation of complementarity-determining region of a mouse monoclonal antibody b-b10 specific to a human interleukin-2 receptor into a human antody; genetic engineering
03/23/1999US5886151 An isolated and purified dna molecule encoding candida albicans protein with integrin-like motifs; for use in vaccines
03/23/1999US5886150 Peptides capable of binding to the GAP protein SH3 domain, nucleotide sequences coding therefor, and preparation and use thereof
03/23/1999US5886145 Isolated nucleic acid molecules, peptides which form complexes with MHC molecule HLA-A2 and uses thereof
03/23/1999US5885966 Immunological castration; (lhrh-luteinizing hormone releasing hormone)
03/23/1999US5885828 SecA gene of mycobacterium tuberculosis and related methods and compositions
03/23/1999US5885823 Bacteria strain atcc no.55783 are incubated in an oxygen concentration of from about 0 percent to about 18 percent, agitating the bacteria in suspension; veterinary medicine
03/23/1999US5885814 Vaccine containing a serine protease
03/23/1999US5885805 gbpA
03/23/1999US5885804 Genetic engineered polynucleotides and encoded polypeptides of the atp-binding protein family, treating meningitis, infection of cerebrospinal fluid
03/23/1999US5885800 DNA encoding tumor necrosis related receptor, TR4
03/23/1999US5885777 A nucleotide sequence encoding an active phosphatidylinositol-3-kinase consisting of specific amino acid sequences or a nucleotide sequence which hybridizes with above nucleotide sequences after washing in low salt buffer
03/23/1999US5885768 Immunogenic peptides derived from the orf1, orf2, and orf3 regions of hepatitis e virus (hev), diagnostic reagents containing the peptide antigens, vaccine compositions containing the antigens, antibodies
03/23/1999US5885589 Pasteurella vaccine
03/23/1999US5885588 Schizophrenia associated with an autoimmune reaction initiated by an infection can be treated by injection comprising dead cell of mycobacterium vaccae
03/23/1999US5885587 Efficacious vaccines against Bordetella pertussis comprising a combination of individually purified pertussis antigens
03/23/1999US5885586 Efficacious vaccines against bordetella pertussis comprising a combination of individually purified pertussis antigens
03/23/1999US5885585 Virus derived from 65th passage of cpv-39; vaccines against canine parvovirus or feline panleukopenia virus
03/23/1999US5885580 A fusion protein obtained by inserting a foreign antigen peptide into the molecular surface of an antigen derived from mycobacteria, has significant increased antigenicity and immunogenicity
03/23/1999US5885576 Vaccines and methods for preventing and treating fescue toxicosis in herbivores
03/23/1999US5885575 Diagnosis and therapy of tumour metastases
03/23/1999US5885574 Antibodies which activate an erythropoietin receptor
03/23/1999US5885573 Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
03/23/1999US5885572 Administering polypeptide or active fragment to treat bacterial infections
03/23/1999US5885570 Induction of tolerance with modified immunogens
03/23/1999US5885568 Coccidiosis poultry vaccine
03/23/1999CA2127462C Treatment for asthma
03/23/1999CA2093513C Methods and compositions for suppressing allograft rejection in mammals
03/23/1999CA2052713C Delivery of agents
03/23/1999CA1340456C Chimeric rodent/human immunoglobulins specific for tumor-associated antigens
03/22/1999CA2244239A1 Novel era
03/22/1999CA2244237A1 A human lig-1 homolog (hlig-1)
03/18/1999WO1999013097A1 Stabilization of helicobacter urease
1 ... 1538 1539 1540 1541 1542 1543 1544 1545 1546 1547 1548 1549 1550 1551 1552 1553 1554 1555 1556 1557 1558 ... 1823